Stockscreener 앱 받기
12.57
1.45%
0.18
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Myriad Genetics Doubles Cancer Testing Rates with Revolutionary Online Screening Tool - StockTitan
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN
Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research - GlobeNewswire Inc.
Myriad Genetics (NASDAQ:MYGN) Updates FY 2024 Earnings Guidance - MarketBeat
Stephens Reaffirms Equal Weight Rating for Myriad Genetics (NASDAQ:MYGN) - MarketBeat
Myriad Genetics stock hits 52-week low at $12.85 amid market challenges - Investing.com Australia
RSI Alert: Myriad Genetics (MYGN) Now Oversold - Nasdaq
Myriad Genetics: Navigating Through A Setback (NASDAQ:MYGN) - Seeking Alpha
Brokerages Set Myriad Genetics, Inc. (NASDAQ:MYGN) Target Price at $24.27 - MarketBeat
Myriad Genetics sees FY24 adjusted EPS 14c-15c, consensus 13c - MSN
Myriad Genetics (NASDAQ:MYGN) Hits New 12-Month LowWhat's Next? - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 2024 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases Q4 Earnings Guidance - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Releases FY25 Earnings Guidance - MarketBeat
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance - The Manila Times
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial ... - The Bakersfield Californian
Myriad Genetics, Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full-Year Ended December 31, 2024 and Full-Year of 2025 - Marketscreener.com
Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6%Here's What Happened - MarketBeat
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Relationship Genetic Tests Market Report 2024, Featuring - GlobeNewswire
Relationship Genetic Tests Market Report 2024, Featuring Profiles of Laboratory Corporation of America, Quest Diagnostics, Cleveland Clinic, Myriad Genetics, Invitae and More - Yahoo Finance
Myriad Genetics FY2024 EPS Estimate Increased by Scotiabank - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Acquired by Nordea Investment Management AB - MarketBeat
MYGN Stock Gains Following Collaboration With Hannah Storm - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Rating Increased to Buy at StockNews.com - MarketBeat
Myriad Genetics Partners with ESPN's Hannah Storm to Champion Breast Cancer Risk Testing - StockTitan
PARP Inhibitor Biomarkers Market Review 2024 and Forecast 2025-2035: Breast Cancer Applications Lead in Revenue, While Ovarian Cancer Emerges as the Fastest-Growing Opportunity - Yahoo Finance UK
Myriad Genetics and MD Anderson Launch Strategic Partnership to Advance MRD Assays - Zenopa
UPDATEMyriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - StockTitan
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Myriad Genetics to Present at J.P. Morgan Healthcare Conference 2024 with Live Webcast - StockTitan
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 45% Undervalued - Simply Wall St
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay - MD Anderson Cancer Center
MD Anderson, Myriad Genetics Partner on Revolutionary Cancer Detection Technology - StockTitan
Myriad Genetics Inc (MYGN) Q2 2024 Earnings: Revenue Surpasses E - GuruFocus.com
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report - The Manila Times
(MYGN) On The My Stocks Page - Stock Traders Daily
Liquid biopsy in cancer diagnostics market is expected to grow at a CAGR of 16.64% by 2030, estimates - EIN News
How to Take Advantage of moves in (MYGN) - Stock Traders Daily
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of "Hold" from Analysts - MarketBeat
MYGN Stock Might Gain From the New Recognition of RiskScore Study - MSN
Barclays PLC Increases Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
PARP Inhibitor Biomarkers Market Investment Outlook: Industry - openPR
Pancreatic Cancer Market Analysis 2024: Trends, Growth, and Key - openPR
Myriad Genetics’ RiskScore Study Named One of the Top 10 - GlobeNewswire
Myriad Genetics' Breakthrough Cancer Test Named Top 10 Genomic Advance by Leading Journal - StockTitan
Hereditary Cancer Testing Market: Pioneering Early Detection and Prevention Strategies - openPR
2.28%
자본화:
|
볼륨(24시간):